Sanofi's (SNY) U300 "next-generation insulin" helped control the amount of sugar in the blood of...


Sanofi's (SNY) U300 "next-generation insulin" helped control the amount of sugar in the blood of diabetes patients in two Phase III trials, with fewer subjects suffering from dangerously low levels than with the company's blockbuster Lantus drug. The results of the testing are vital to Sanofi, as Lantus, which generated sales of €4.96B last year, is due to lose patent protection in 2015. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs